Apotex, Inc.

Description

Apotex Inc., announced that on December 6, 2011, the Federal Court of Canada ruled in favour of Apotex, clearing the way to deliver their generic version of Plavix®, Apo-Clopidogrel, to the Canadian market. Apotex challenged the Sanofi-aventis Plavix® patents for over 8 years, through two Federal Court systems and multiple levels of judicial review including the Supreme Court of Canada.

Committed to advancing generics, Apotex has been in the business for over 36 years and during that time has developed a deep understanding of the global market and the skills and experience needed to succeed in areas of sales, marketing, product development, clinical development, regulatory and medical affairs.

Apotex is the largest Canadian owned pharmaceutical organization in Canada and a leading producer in North America. While serving a marketplace of over 115 countries, we are committed to growth in Canada, using Canadian resources. Our staff thrives on what our fast-paced environment offers - the infrastructure to provide a greater variety of products for global betterment.

Apotex Inc. the largest Canadian owned pharmaceutical company, launched today Apo-Rosuvastatin, a generic version of Crestor® produced by AstraZeneca. The Apotex product is 100% Canadian made by employees and facilities dedicated to ensuring that Canada remains a global strength in generic product introduction. With annual Crestor® brand sales in Canada of over $700 million, generic Rosuvastatin represents the second largest generic product launch in this market to date.

Products Access our product catalogue, discover our latest products, and optimise your time using our catalog services.

Products & services

Similar companies nearby